Viking Therapeutics, Inc. (VKTX)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Viking Therapeutics, Inc. reported revenue of $0. The company ran a net loss. It held $715.73M in total assets against $76.67M in total liabilities.
Key ratios (FY2025)
-56.3%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Operating Income | -$393.34M | -$150.92M | -$100.83M | -$70.36M | -$55.68M | -$42.66M | -$32.69M | -$26.16M | -$19.07M | -$13.85M |
| Net Income | -$359.64M | -$109.96M | -$85.89M | -$68.87M | -$54.99M | -$39.49M | -$25.78M | -$22.06M | -$20.58M | -$14.73M |
| EPS (Diluted) | $-3.19 | $-1.01 | $-0.91 | $-0.90 | $-0.71 | — | — | — | — | — |
| Total Assets | $715.73M | $908.32M | $368.49M | $168.53M | $210.66M | $256.50M | $284.26M | $302.31M | $22.12M | $14.54M |
| Total Liabilities | $76.67M | $28.04M | $20.07M | $23.21M | $8.78M | $12.16M | $7.14M | $4.56M | $8.66M | $6.49M |
| Shareholders' Equity | $639.06M | $880.28M | $348.42M | $145.32M | $201.88M | $244.34M | $277.12M | $297.75M | $13.46M | $8.04M |
| Cash & Equivalents | $165.81M | $26.68M | $55.52M | $36.63M | $26.37M | $29.12M | $8.38M | $24.78M | $8.99M | $3.08M |
| Operating Cash Flow | -$278.69M | -$87.79M | -$73.38M | -$48.40M | -$47.59M | -$21.78M | -$24.75M | -$18.75M | -$14.76M | — |
| Shares Outstanding | 114.79M | 111.57M | 100.11M | 78.26M | 78.25M | 73.22M | 72.41M | 71.74M | 35.82M | 20.82M |